The Israel Parkinson Association welcomed with“excitement and joy” the results of a study showing Parkinson’s drug Azilect (rasagiline), developed by Profs. Moussa Youdim and John Finberg of the Technion-Israel Institute of Technology, to be effective at slowing the progression of the chronic and fatal neurological disease, a first for any drug.
In the randomized, double-blind ADAGIO study, the drug was found to be effective, safe, and well tolerated. Based on these results, the drug could become the first Parkinson’s disease treatment in the world to receive a label for “disease modification.” Azilect received the approval of the U.S. Food and Drug Administration for sale in the spring of 2006.
By Judy Siegel-Itzkovich, www.JPost.com